Matisse Capital Takes Position in Pfizer Inc. $PFE

Matisse Capital purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 11,627 shares of the biopharmaceutical company’s stock, valued at approximately $282,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter valued at $27,000. North Capital Inc. bought a new position in Pfizer during the 1st quarter valued at $28,000. Bayforest Capital Ltd bought a new position in Pfizer during the 1st quarter valued at $28,000. Horizon Financial Services LLC bought a new position in Pfizer during the 1st quarter valued at $35,000. Finally, WPG Advisers LLC bought a new position in Pfizer during the 1st quarter valued at $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.6%

NYSE PFE opened at $26.27 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market cap of $149.36 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55. The firm’s 50 day moving average price is $24.76 and its two-hundred day moving average price is $24.14.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the company posted $0.60 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.